Traditional Chinese/herbal medicine (TCM) is now commonly used by cancer patients of Asian ethnicity to supplement or replace prescribed treatments. The overall survival rate for lung cancer has not improved significantly in the past several decades; it remains the leading cause of cancer death. Much more attention has been paid by clinicians and researchers to the possible use of compound Chinese medicine (CCM) as effective anti-lung cancer medicines. In this review, we briefly summarize the clinical and experimental status of numerous CCMs recently developed primarily in China for the treatment of lung cancer, including formulations, treatment effectiveness, and molecular mechanisms. By presenting this information, our goal is to possibly open up new future avenues for the practice of lung cancer treatment.
Due to the plethora of new approaches being used in modern drug discovery by the pharmaceutical industry, Current Drug Discovery Technologies has been established to provide comprehensive overviews of all the major modern techniques and technologies used in drug design and discovery. The journal is the forum for publishing both original research papers and reviews describing novel approaches and cutting edge technologies used in all stages of drug discovery. The journal addresses the multidimensional challenges of drug discovery science including integration issues of the drug discovery process.
Current Drug Discovery Technologies is an essential journal for all scientists and research managers involved in drug discovery who wish to keep abreast of all the modern techniques and technologies used in drug discovery.